BPC-157 Deep-Dive
Also known as: Body Protection Compound 157 · Pentadecapeptide BPC 157 · PL 14736
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a protective sequence isolated from human gastric juice. Researchers investigate its modulation of nitric oxide signaling, VEGFR2 upregulation, and growth-factor expression at sites of connective-tissue injury — proposed mechanisms for the angiogenic and cytoprotective effects observed in animal models.
Plasma Half-Life
~30 minutes
Logarithmic scale · 30 min mapped
Tissue Residency
Tissue residency proposed (hours to days at injection site)
Quick Facts
- Typical dose
- 250–500 mcg, 1–2x daily
- Range
- 200 mcg – 750 mcg per dose
- Route
- Subcutaneous (systemic) or local injection near site of interest. Oral formulations are investigated for gastrointestinal applications.
- Cycle pattern
- Common practitioner pattern: 4–6 weeks on, 2–4 weeks off. Some protocols run continuous 8–12 week blocks for chronic connective-tissue research.
- Primary evidence tier
- Expert
Mechanism of Action
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a protective sequence isolated from human gastric juice. Researchers investigate its modulation of nitric oxide signaling, VEGFR2 upregulation, and growth-factor expression at sites of connective-tissue injury — proposed mechanisms for the angiogenic and cytoprotective effects observed in animal models.
Researchers investigate BPC-157 in the broader context of the Healingcompound class. The compound's proposed relationship to underlying physiology is typically framed against the Inflammation axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, BPC-157's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life ~30 minutes) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
~30 minutes
Logarithmic scale · 30 min mapped
Tissue Residency
Tissue residency proposed (hours to days at injection site)
BPC-157 has a plasma half-life of approximately ~30 minutes. This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, tissue residency proposed (hours to days at injection site). This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of BPC-157alongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from 10,000+ hours of clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians who run high-volume peptide practices report BPC-157 as one of the most-requested compounds, almost always for tendon, ligament, or gut-lining research applications. In protocol audits we've reviewed, the most consistent feedback pattern is that subcutaneous administration near the area of interest produces faster subjective response than distal-site injection — a finding that aligns with the proposed tissue-residency mechanism. Practitioners typically pair it with TB-500 for synergistic recovery research and caution that the 30-minute plasma half-life argues for split daily dosing rather than once-daily protocols.
Dosing
250–500 mcg, 1–2x daily
Subcutaneous (systemic) or local injection near site of interest. Oral formulations are investigated for gastrointestinal applications.
Cycle
Common practitioner pattern: 4–6 weeks on, 2–4 weeks off. Some protocols run continuous 8–12 week blocks for chronic connective-tissue research.
Evidence Breakdown
Every finding about BPC-157is categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Limited human clinical data; most evidence from rodent gastric-ulcer and tendon-injury models.
- Practitioner consensus across high-volume peptide clinics treats BPC-157 as a first-line recovery research tool with a strong subjective-response track record.
- Emerging in-vitro work explores neuroprotective and gut-brain-axis applications; community protocol logs report consistent results in tendon/ligament research.
Cycling & Stack Considerations
Cycling Protocol
Common practitioner pattern: 4–6 weeks on, 2–4 weeks off. Some protocols run continuous 8–12 week blocks for chronic connective-tissue research.
Common Stacks
- •BPC-157 + TB-500 (the canonical recovery pairing)
- •BPC-157 + GHK-Cu (connective-tissue + dermal protocols)
- •BPC-157 + Ipamorelin (pulse + repair stack)
Interactions & Overlap
- •TB-500 (frequently co-investigated; mechanistically complementary, no documented adverse interaction)
- •GHK-Cu (often layered for connective-tissue research)
- •NSAIDs (some practitioner reports suggest reduced subjective benefit when stacked; mechanism unclear)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Active malignancy — angiogenic mechanisms theoretically contraindicated until further research clarifies risk
- Pregnancy and lactation — no human safety data
- Concurrent investigational use with other angiogenic agents without supervision
BPC-157 FAQs
What is the typical BPC-157 dosage range?
Practitioner protocols most commonly cite 250–500 mcg, dosed once or twice daily via subcutaneous injection. Some research applications use up to 750 mcg per dose. The short ~30-minute plasma half-life argues for split daily dosing rather than a single daily injection.
What is the half-life of BPC-157?
Plasma half-life is approximately 30 minutes. Practitioner observation and proposed mechanism suggest tissue residency at the injection site extends functional duration well beyond the plasma window — which is why local administration near the area of interest is a common protocol choice.
Can BPC-157 be taken orally?
Oral formulations are investigated primarily for gastrointestinal research applications, where direct gut-lumen exposure is desired. For systemic or local connective-tissue research, subcutaneous administration is the dominant practitioner protocol.
How long does it take to see results from BPC-157?
In protocol audits we've reviewed, subjective response timelines vary widely. Practitioners generally cite 2–4 weeks as a common observation window for connective-tissue research applications, with some protocols extending to 6–8 weeks before assessing outcomes.
Is BPC-157 stacked with TB-500?
Yes — BPC-157 + TB-500 is the canonical recovery pairing in practitioner protocols. The two compounds are mechanistically complementary (BPC-157's angiogenic / cytoprotective profile alongside TB-500's actin-binding / cell-migration profile) and no adverse interaction has been documented in the practitioner literature.
What are the side effects of BPC-157?
The practitioner safety profile is generally regarded as favorable, with most reports limited to transient injection-site reactions. Theoretical concerns about angiogenic mechanisms and malignancy remain unresolved in the absence of long-term human data.
Is BPC-157 FDA approved?
BPC-157 is not FDA approved for any indication and is not intended to diagnose, treat, cure, or prevent any disease. It is sold for research use only.
Related Compounds
Track your BPC-157 protocol in DoseCraft
The PK-aware protocol builder models ~30 minutes decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.